FIELD: medicine.
SUBSTANCE: present invention relates to medicine, namely to the use of a pegylated recombinant chimeric mouse fibroblast-21 growth factor. The use of the pegylated recombinant chimeric mouse fibroblast-21 growth factor or its pharmaceutically acceptable salt in a composition of drugs for the treatment of non-alcoholic steatohepatitis is described, where the use is selected from reduction in lobular inflammation.
EFFECT: above-described use allows for effective reduction in lobular inflammation.
8 cl, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN | 2016 |
|
RU2697523C2 |
| PHARMACEUTICAL COMBINATION CONTAINING SILYBIN | 2016 |
|
RU2695224C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND RADIX PUERARIAE EXTRACT | 2016 |
|
RU2697670C2 |
| TREATMENT OF HEPATIC ADIPOSITIS WITH APPLICATION OF GLUCOCORTICOID AND MINERALOCORTICOID RECEPTOR ANTAGONISTS | 2015 |
|
RU2718921C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND L-CARNITINE | 2016 |
|
RU2699011C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN AND VITAMIN E | 2016 |
|
RU2695806C2 |
| PHARMACEUTICAL COMPOSITION CONTAINING SILYBIN, VITAMIN E AND L-CARNITINE | 2016 |
|
RU2700793C2 |
| THERAPEUTIC AGENT FOR LIVER DISEASES | 2018 |
|
RU2723686C1 |
| PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING NON-ALCOHOLIC FATTY LIVER INFILTRATION, CONTAINING GPR119 LIGAND AS ACTIVE INGREDIENT | 2019 |
|
RU2768943C1 |
| METHOD OF TREATING NON-ALCOHOLIC STEATOHEPATITIS (NASH) WITH USING CYSTEAMINE PRODUCTS | 2008 |
|
RU2498795C2 |
